Generate Biomedicines, Inc.

Generate Biomedicines, Inc. (GENB) priced its initial public offering on Feb 27, 2026 at $16.00 per share, raising $400M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $2.04B. Goodwin Procter advised the company and Latham & Watkins advised the underwriters.

Generate Biomedicines, Inc. is a clinical-stage generative biology company that uses AI to design and develop therapeutics. Its Generate Platform integrates computational methods with scalable biohardware and is not tied to a therapeutic area or protein modality.

Status

IPO

Ticker

GENB

Exchange

Nasdaq Global Select

Priced

Feb 27, 2026

IPO price

$16.00

Raised

$400M

Market cap at IPO price

$2.04B

First filed

Feb 4, 2026

Company counsel

Goodwin Procter

Underwriters' counsel

Latham & Watkins

Sector

Biotech & pharma

Country / state

MA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.